Aligos Therapeutics Valuation
| ALGS Stock | USD 25.51 2.52 10.96% |
At this time, the firm appears to be overvalued. Aligos Therapeutics shows a prevailing Real Value of $11.36 per share. The current price of the firm is $25.51. Our model approximates the value of Aligos Therapeutics from analyzing the firm fundamentals such as Operating Margin of (15.86) %, shares outstanding of 3.46 M, and Return On Equity of -1.47 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Aligos Therapeutics' valuation include:
Price Book 1.827 | Enterprise Value 25.7 M | Enterprise Value Ebitda 0.5749 | Price Sales 14.736 | Enterprise Value Revenue 4.2918 |
Overvalued
Today
Please note that Aligos Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Aligos Therapeutics is based on 3 months time horizon. Increasing Aligos Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Aligos stock is determined by what a typical buyer is willing to pay for full or partial control of Aligos Therapeutics. Since Aligos Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aligos Stock. However, Aligos Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.51 | Real 11.36 | Target 4.0 | Hype 26.23 |
The intrinsic value of Aligos Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aligos Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Aligos Therapeutics helps investors to forecast how Aligos stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aligos Therapeutics more accurately as focusing exclusively on Aligos Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Aligos Therapeutics' intrinsic value based on its ongoing forecasts of Aligos Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Aligos Therapeutics' closest peers.
Aligos Therapeutics Cash |
|
Aligos Valuation Trend
Aligos Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Aligos Therapeutics' financial worth over time. Using both Aligos Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Aligos Therapeutics Total Value Analysis
Aligos Therapeutics is presently forecasted to have valuation of 25.74 M with market capitalization of 88.37 M, debt of 11.14 M, and cash on hands of 159.34 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Aligos Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
25.74 M | 88.37 M | 11.14 M | 159.34 M |
Aligos Therapeutics Investor Information
About 18.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.83. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aligos Therapeutics recorded a loss per share of 7.25. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 19th of August 2024. Based on the key indicators related to Aligos Therapeutics' liquidity, profitability, solvency, and operating efficiency, Aligos Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Aligos Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aligos Therapeutics has an asset utilization ratio of 10.25 percent. This implies that the Company is making $0.1 for each dollar of assets. An increasing asset utilization means that Aligos Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Aligos Therapeutics Ownership Allocation
The market capitalization of Aligos Therapeutics is $88.37 Million. 30% of Aligos Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Aligos Therapeutics Profitability Analysis
The company reported the previous year's revenue of 15.53 M. Net Loss for the year was (87.68 M) with loss before overhead, payroll, taxes, and interest of (71.17 M).About Aligos Therapeutics Valuation
The stock valuation mechanism determines Aligos Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Aligos Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aligos Therapeutics. We calculate exposure to Aligos Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aligos Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 12.5 M | 13.1 M | |
| Pretax Profit Margin | (5.59) | (5.87) | |
| Operating Profit Margin | (5.67) | (5.96) | |
| Net Loss | (5.65) | (5.93) | |
| Gross Profit Margin | 0.80 | 0.84 |
Aligos Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Aligos Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 24.9 M |
Aligos Therapeutics Current Valuation Indicators
Aligos Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Aligos Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Aligos Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Aligos Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Aligos Therapeutics' worth.Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.